A rterial hypertension is now the largest contributor to premature morbidity and mortality worldwide.
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the mechanisms underlying the regulation of NCC by WNK1 and WNK4. The results were, however, often contradictory and did not allow the establishment of a clear and unifying model to explain how WNKs regulate the expression and activity of the cotransporter. We first reported that WNK4 inhibits NCC activity in Xenopus laevis oocytes, 6, 7 an effect reversed by angiotensin II. 8 This inhibitory effect was also observed in mouse DCT cells, 9 endogenously expressing WNK4 and NCC, suggesting that it is not an overexpression artifact. The mechanisms by which WNK1 regulates NCC are less well defined. Biochemical studies showed that the catalytically active WNK1 isoform, Long-WNK1 (L-WNK1), activates the Ste20 proline-alaninerich kinase (SPAK), 10, 11 responsible for phosphorylating and activating NCC directly. 12 However, these data were not supported by studies performed in Xenopus oocytes. In this system, L-WNK1 failed to activate NCC but relieved NCC from WNK4-mediated inhibition, 7 suggesting that L-WNK1 lies upstream of WNK4 to activate NCC. The apparent discrepancies between results obtained using different model systems have generated substantial confusion concerning WNK effects.
To identify the pathway(s) involved in vivo in WNK1-dependent activation of NCC, we generated a mouse model of FHHt caused by WNK1 mutations (WNK1 +/FHHt mice). 13 This model exhibited a full FHHt phenotype, resulting from an increased expression of L-WNK1 in the DCT and, to a lesser extent, in the connecting tubule. As expected, the abundance of total and phosphorylated NCC at the apical membrane of DCT cells was enhanced. We also showed that phosphorylated SPAK abundance is increased near the apical membrane of DCT cells of mutant mice. These data support the existence of a WNK1/SPAK/NCC cascade but do not indicate whether SPAK/NCC is stimulated directly by WNK1 or whether the effects result from relief of WNK4 inhibition.
The present study therefore tested the role of WNK1-WNK4 interaction in vitro and in vivo. Our results provide evidence that WNK1 is a powerful activator of NCC, independent of WNK4. In addition, we show that WNK4 antagonizes the activating effect of WNK1 on the cotransporter. Together, these results help resolve existing controversies and elucidate the mechanisms by which L-WNK1 and WNK4 signal to NCC.
Methods
A detailed Methods section is available in the online-only Data Supplement.
Results

WNK1-FHHt Mice Retain the Full FHHt Phenotype in the Absence of WNK4
Mutations identified at the WNK1 locus in patients with FHHt are large deletions of the first intron. 3 We recently developed a mouse model for WNK1-FHHt by deleting the first intron of mouse WNK1 (WNK1 +/FHHt mice). 13 This model recapitulates the FHHt phenotype, with elevated arterial pressure, hyperkalemia, and hyperchloremic metabolic acidosis. We used these mice to test the interaction between WNK1 and WNK4 in vivo, by crossing the WNK1 +/FHHt animals with WNK4 −/− mice. The latter displayed decreased abundance of total and phosphorylated NCC, associated with hypochloremic metabolic alkalosis and increased renin and hematocrit. 14 . Moreover, the increased NCC expression and phosphorylation seen in WNK1 +/FHHt mice were still present in the double mutants ( Figure 1B) .
We did not measure the blood pressure of WNK4 −/− mice as previous studies, including ours, reported that it was not different from that of control mice.
14,15 However, we measured renin expression and found that it was increased in WNK4 −/− mice, similar to what we showed previously.
14 Finally, it is important to note that we used the tail-cuff method to measure the blood pressure of all mice. Although methods using tail cuff are validated and approved, such methods are less sensitive than telemetric ones. Thus, small differences in arterial pressure may have gone undetected in the current study. 16 These data show that WNK1 mutations cause FHHt by increasing the level of expression of L-WNK1 in the distal nephron, which then activates NCC independently of WNK4. As prior studies by others and ourselves 7, 17 found that L-WNK1 did not regulate NCC directly in Xenopus oocytes, we decided to revisit the effects of L-WNK1 in this system and in cells.
Kidney-Enriched L-WNK1 Isoform Activates NCC in a SPAK-Dependent Manner
Several isoforms of WNK1 are generated by alternative splicing of 8 exons in humans and mice, and we showed that the isoform lacking only exon 11 (L-WNK1-Δ11) is the major variant in the nephron (≈70% of all WNK1 isoforms). 18 This isoform was, however, not the one used in the studies aimed at characterizing the regulation of NCC by L-WNK1, 7 which used the isoform lacking both exons 11 and 12. 19 Therefore, the lack of L-WNK1 effect on NCC in expression systems could be because of the use of this isoform. We tested the effect of the L-WNK1 variants on NCC activity in Xenopus oocytes and human embryonic kidney 293 (HEK293) cells. L-WNK1-Δ11 induced a 3.25-fold Figure  S1 in the online-only Data Supplement). With the exception of L-WNK1-Δ9, variants containing all exons or a combination of the alternatively spliced exons 9, 11, and 12 also activated NCC, but significantly less than L-WNK1-Δ11 ( Figure 2A ). This effect was kinase dependent as it was absent when WNK1 D368A, known to lack kinase activity, 19 was used ( Figure 2B ). Previous studies did not observe the direct activation of NCC by the rat L-WNK1-Δ11 to 12 variant first because it is less potent than L-WNK1-Δ11 ( Figure 2A ) and, second, because it carries a previously unsuspected mutation in the C-terminal domain, identified by sequencing (G2120S; Figure S2A ). This mutation reduced the effect of L-WNK1 on the cotransporter. Replacing the serine residue by a glycine in the rat L-WNK1-Δ11 to 12 cDNA restored NCC activation ( Figure S2B ), whereas mutating the glycine into a serine in the human L-WNK1-Δ11 cDNA prevented NCC activation ( Figure S2C ).
To test the requirement for SPAK in L-WNK1-mediated activation of NCC, we disrupted the L-WNK1/SPAK interaction by eliminating a SPAK-binding motif in L-WNK1-Δ11. Disruption of a similar motif in WNK3 blocks its ability to activate NCC. 20 This mutant (L-WNK1-Δ11-F316A) not only failed to stimulate NCC but also inhibited the cotransporter ( Figure 2B ). Because oocytes express L-WNK1 21 and L-WNK1 oligomerizes, 22 we hypothesized that L-WNK1-Δ11-F316A exerted this effect through interactions with endogenous L-WNK1. Thastrup et al 23 showed that a small HQ motif (HIQEVVSLQT), located in the C-terminal coiled-coil domain, is essential for the formation of homo and heteromers of WNK kinases. The replacement of the HIQEVVSLQT sequence by AIQEVVSLAT impairs the interaction of WNK kinases. 23 Introduction of these mutations into L-WNK1-Δ11 (Δ11HQ/AA) prevented the activation of NCC. Moreover, mutation of the HQ motif of L-WNK1-Δ11-F316A abrogated its inhibition (Δ11-F136A-HQ/AA; Figure 2B ). This suggests that basal NCC activity in vitro is dependent on endogenous L-WNK1 and that L-WNK1-Δ11-F316A acts as dominant negative form. To confirm that basal NCC activity in vitro requires endogenous L-WNK1 activity, we used NCC-transfected mammalian kidney cells, which express, glycosylate, and phosphorylate NCC in a manner that resembles mammalian kidney ( Figure S3 ). Overexpression of human L-WNK1-Δ11 increased the abundance of total and phosphorylated NCC ( Figure 2C ). Conversely, L-WNK1 small interfering RNA-mediated knockdown ( Figure 2D ) reduced phosphorylated NCC abundance. These results demonstrate that kidney-enriched isoform of L-WNK1 is a powerful activator of NCC through a WNK4-independent mechanism because WNK4 is not expressed in HEK293 cells ( Figure S3 ).
L-WNK1 Effect on NCC Is Antagonized by WNK4
WNK4 inhibits NCC in Xenopus oocytes, 6 ,7 mammalian cells, 24 and mice. 25 In addition, WNK4 prevents the positive effect exerted by WNK3 on NCC 26 ( Figure 3A) . We observed the same effect when WNK4 and L-WNK1-Δ11 were coexpressed, in Xenopus oocytes and HEK293 cells ( Figure 3A and 3B). The decreased NCC activity observed when WNK4 and L-WNK1-Δ11 are coexpressed could result from the inhibition of L-WNK1-Δ11 by WNK4 or from the parallel action of an activator (L-WNK1-Δ11) and an inhibitor (WNK4). The former could be caused by a reduced L-WNK1-∆11 abundance mediated by WNK4. Figure 3C and 3D shows that WNK4 significantly reduced the abundance of L-WNK1-∆11 in both oocytes and HEK293 cells. The effects to reduce L-WNK1 were not simply the result of an overexpression artifact. Indeed, overexpression of WNK3 did not modify L-WNK1-∆11 ( Figure S4A ) and overexpression of WNK4 did not affect SPAK or pSPAK abundance in HEK293 cells ( Figure S4B ).
We next assessed the requirement for the formation of WNK4 oligomers by mutating the C-terminal HQ motif. 23 The resulting WNK4-HQ/AA mutant lost the capacity to inhibit NCC ( Figure 3E ) and precluded the ability of WNK4 to inhibit L-WNK1-induced or WNK3-induced activation of NCC in oocytes ( Figure 3E ). These functional observations indicate that interactions of WNKs kinases via the HQ motif are necessary for their effects on NCC.
Discussion
Since the discovery of WNK kinases and their relation to FHHt, an inherited disease featuring arterial hypertension, a great deal of effort has been directed at understanding how WNK kinase mutations produce the disease. As all FHHt symptoms are corrected by a thiazide treatment and as the expression of the Na-Cl cotransporter NCC is increased in FHHt mouse models, several groups aimed at understanding how the WNK kinases modulate NCC activity. However, the results thus obtained failed to generate an unifying model. In the present study, we show data supporting a revised model of WNK kinase action in signaling to NCC, in which WNK1 and WNK3 mediate activation of NCC through SPAK, and WNK4 antagonizes WNK1 and WNK3 (Figure 4) . This model can explain several contradictory observations. First, the demonstration that L-WNK1 is a strong stimulator of NCC activity clarifies the pathophysiology of FHHt ( Figure  S5 ) because increased L-WNK1 expression in the DCT is sufficient to promote the development of the FHHt phenotype. 13 Second, it fits with the in vitro observations that L-WNK1 is a more powerful activator of SPAK than WNK4. 11 Third, the new model provides a plausible explanation for the discrepancy between the mild phenotype consequent to WNK3 deletion in vivo, and the powerful ability of WNK3 to activate NCC in vitro. 26, 27 Because both WNK1 and WNK3 can activate NCC, the increased WNK1 expression observed in WNK3 −/− mice likely compensates for the loss of WNK3. 28, 29 Previous studies failed to demonstrate the WNK1 effect on NCC for 2 reasons. First, those studies did not use the L-WNK1 isoform lacking exon 11, the most abundant isoform along the nephron 18 and the most powerful NCC activator. Instead, the studies used an isoform lacking both exons 11 and 12, which represents only 20% of WNK1 isoforms in the kidney. 18 Second, the previously used rat L-WNK1-Δ11 to 12 cDNA carries a mutation in the C-terminal region of the protein that reduces its effect on NCC. This cDNA corresponds to the first isolated L-WNK1 cDNA, which was subcloned from a rat brain library, 19 where the variant missing both exons 11 and 12 is the predominant variant. 18 Coexpression of L-WNK1-Δ11 and WNK4 results in a decreased NCC activity compared with L-WNK1-Δ11 alone. This could result from the inhibition of L-WNK1-Δ11 by WNK4 or from the parallel action of an activator (L-WNK1-Δ11) and an inhibitor (WNK4). WNK kinases can form homo or heteromers via a conserved carboxyl-terminal domain. 22, 30 Coimmunoprecipitation experiments indicated that L-WNK1 interacts with both WNK4 and WNK3 in HEK293 cells through a C-terminal conserved HQ motif. 23 We show here that the interaction among L-WNK1-Δ11, WNK3, and WNK4 is essential for the regulation of NCC, as the mutation of their HQ motif abrogates the effect of all 3 kinases. Our study does not, however, allow us to determine which homo or heteromers are required for NCC regulation. The disruption of the interaction by mutating the HQ motif results in a decreased capacity of WNK3 to autophosphorylate and phosphorylate WNK1 on the T-loop residue (Ser382), 23 required for WNK1 activation. Inhibiting the formation of activating WNK3 homomers and L-WNK1/WNK3 heteromers could therefore prevent the activation of NCC by L-WNK1 or WNK3 in oocytes. Similarly, preventing the formation of WNK4 homomers reduced its autophosphorylation. Interestingly, Thastrup et al 23 showed that, although WNK4 can interact with WNK1, it is unable to phosphorylate its T-loop residue. The expression of WNK4 in oocytes could thus result in the formation of inhibitory WNK4 homomers and L-WNK1/WNK4 or WNK3/WNK4 heteromers, in which L-WNK1 or WNK3 is not activated (Figure 4) . The expression of WNK4-HQ mutant in Xenopus oocytes would then restore NCC activity by preventing the formation of these inhibitory homomers and heteromers.
The present study reconciles in vivo and in vitro observations about the mode of L-WNK1 action toward NCC, but controversy still remains concerning intrinsic WNK4 activity. Most in vitro studies, including the present one, concluded that WNK4 is an inhibitor of NCC, either when overexpressed in Xenopus oocytes and mammalian cells 6, 7, 24 or when endogenous WNK4 is knocked down in mDCT15 cells. 9 These results are supported by some but not all in vivo studies. Lalioti et al 25 first reported that WNK4 overexpression in transgenic mice results in a decreased NCC expression, again suggesting that WNK4 inhibits the cotransporter. This conclusion is however not supported by 2 subsequent studies. First, WNK4 inactivation in mice causes a dramatic reduction of NCC abundance and phosphorylation.
14,15 Second, Wakabayashi et al 31 observed that WNK4 overexpression caused FHHt in mice, although they used the same transgene than the one used in Lalioti's study. These 2 studies suggest that WNK4 is an activator of NCC, in vivo.
How could we reconcile the WNK4 inhibitory effect observed in vitro and in vivo with the activating effect observed in vivo? NCC inhibition by WNK4 in Xenopus can be abrogated by angiotensin II. 8 Similarly, the phosphorylation of SPAK by WNK4 is stimulated by an increased Ca 2+ concentration. 32 One could therefore speculate that WNK4 inhibitory and stimulatory actions coexist and can be modulated by intracellular signals and that the environment of in situ DCT cells at baseline favors the activating mode of WNK4 , whereas the culture conditions of oocytes or mammalian cells mostly favors its inhibitory mode.
Perspectives
We present evidence that the kidney-enriched isoform of L-WNK1 stimulates NCC expression and activity in a SPAKdependent manner and not through modulation of an inhibitory effect of WNK4, as previously reported. In addition, we show that WNK4 antagonizes WNK1-or WNK3-mediated activation of the cotransporter. A lot of questions, however, remain open before we can fully understand how the WNK kinases interact with each other to regulate the activity of the Na-Cl cotransporter. We think that one of the most important issues is to determine the WNK's relative expression level in the DCT and the characterization of the oligomers truly formed by WNK1, WNK3, and WNK4 in vivo.
